Ignite Creation Date:
2025-12-25 @ 5:12 AM
Ignite Modification Date:
2026-02-11 @ 4:47 AM
Study NCT ID:
NCT02781727
Status:
COMPLETED
Last Update Posted:
2022-01-04
First Post:
2016-05-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Sponsor:
Ascendis Pharma Endocrinology Division A/S
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
TransCon hGH CT-301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None